Vident Advisory, LLC Intellia Therapeutics, Inc. Transaction History

Vident Advisory, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$20.02 - $27.22 $42,702 - $58,060	2,133 Added 12.2%	19,621 $439 Million
Q1 2024 May 14, 2024	BUY	$23.82 - $32.8 $24,367 - $33,554	1,023 Added 6.21%	17,488 $481 Million
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $16,003 - $22,346	691 Added 4.38%	16,465 $502 Million
Q3 2023 Feb 21, 2024	SELL	$31.62 - $45.78 $21,849 - $31,633	-691 Reduced 4.2%	15,774 $499 Million
Q3 2023 Nov 14, 2023	BUY	$31.62 - $45.78 $498,773 - $722,133	15,774 New	15,774 $499 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $867M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Advisory, LLC with notifications on news.